Callan Capital buys $960,300 stake in Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NBIX) : Callan Capital scooped up 7,000 additional shares in Neurocrine Biosciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 22,000 shares of Neurocrine Biosciences which is valued at $960,300.Neurocrine Biosciences makes up approximately 0.41% of Callan Capital’s portfolio.

Other Hedge Funds, Including , Palisade Capital Managementnj reduced its stake in NBIX by selling 61,455 shares or 29.74% in the most recent quarter. The Hedge Fund company now holds 145,162 shares of NBIX which is valued at $6.3 Million. Neurocrine Biosciences makes up approx 0.25% of Palisade Capital Managementnj’s portfolio.Proshare Advisors reduced its stake in NBIX by selling 8,552 shares or 10.09% in the most recent quarter. The Hedge Fund company now holds 76,167 shares of NBIX which is valued at $3.3 Million. Neurocrine Biosciences makes up approx 0.05% of Proshare Advisors’s portfolio.Russell Frank Co reduced its stake in NBIX by selling 19,304 shares or 36.18% in the most recent quarter. The Hedge Fund company now holds 34,054 shares of NBIX which is valued at $1.6 Million.Tocqueville Asset Management boosted its stake in NBIX in the latest quarter, The investment management firm added 15,900 additional shares and now holds a total of 41,100 shares of Neurocrine Biosciences which is valued at $1.9 Million. Neurocrine Biosciences makes up approx 0.02% of Tocqueville Asset Management’s portfolio.

Neurocrine Biosciences opened for trading at $43.9 and hit $46.11 on the upside on Monday, eventually ending the session at $45.64, with a gain of 4.56% or 1.99 points. The heightened volatility saw the trading volume jump to 10,12,027 shares. Company has a market cap of $3,955 M.

On the company’s financial health, Neurocrine Biosciences reported $-0.22 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.29. The company had revenue of $15.00 million for the quarter, compared to analysts expectations of $15.43 million. The company’s revenue was down -24.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.01 EPS.

Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.

Leave a Reply

Neurocrine Biosciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Neurocrine Biosciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.